|
1
|
Demetri GD, Antonia S, Benjamin RS, Bui
MM, Casper ES, Conrad EU III, DeLaney TF, Ganjoo KN, Heslin MJ,
Hutchinson RJ, et al: Soft tissue sarcoma. J Natl Compr Canc Netw.
8:630–674. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lima AP, Pereira FC, Almeida MA, Mello FM,
Pires WC, Pinto TM, Delella FK, Felisbino SL, Moreno V, Batista AA
and de Paula Silveira-Lacerda E: Cytoxicity and apoptotic mechanism
of ruthenium(II) amino acid complexes in sarcoma-180 tumor cells.
PLoS One. 9:e1058652014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Paiva GS, Taft CA, Carvalho MC, de Souza
IA, da Silva EC, Cavalcanti KP, L RF Jr and De la Cruz NM: A
comparative study of the effects of vitamins C and E in the
development of sarcoma 180 in mice. J Cancer. 4:724–726. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yi J, Qu H, Wu Y, Wang Z and Wang L: Study
on antitumor, antioxidant and immunoregulatory activities of the
purified polyphenols from pinecone of Pinus koraiensis on
tumor-bearing S180 mice in vivo. Int J Biol Macromol. 94:735–744.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mo L, Chen Y, Li W, Guo S, Wang X, An H
and Zhan Y: Anti-tumor effects of (1→3)-β-d-glucan from
Saccharomyces cerevisiae in S180 tumor-bearing mice. Int J Biol
Macromol. 95:385–392. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Seddon B, Strauss SJ, Whelan J, Leahy M,
Woll PJ, Cowie F, Rothermundt C, Wood Z, Benson C, Ali N, et al:
Gemcitabine and docetaxel versus doxorubicin as first-line
treatment in previously untreated advanced unresectable or
metastatic soft-tissue sarcomas (GeDDiS): A randomised controlled
phase 3 trial. Lancet Oncol. 18:1397–1410. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tap WD, Papai Z, Van Tine BA, Attia S,
Ganjoo KN, Jones RL, Schuetze S, Reed D, Chawla SP, Riedel RF, et
al: Doxorubicin plus evofosfamide versus doxorubicin alone in
locally advanced, unresectable or metastatic soft-tissue sarcoma
(TH CR-406/SARC021): An international, multicentre, open-label,
randomised phase 3 trial. Lancet Oncol. 18:1089–1103. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yang Y and Bedford MT: Protein arginine
methyltransferases and cancer. Nat Rev Cancer. 13:37–50. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bao X, Zhao S, Liu T, Liu Y and Yang X:
Overexpression of PRMT5 promotes tumor cell growth and is
associated with poor disease prognosis in epithelial ovarian
cancer. J Histochem Cytochem. 61:206–217. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dong Y, Song C, Wang Y, Lei Z, Xu F, Guan
H, Chen A and Li F: Inhibition of PRMT5 suppresses osteoclast
differentiation and partially protects against ovariectomy-induced
bone loss through downregulation of CXCL10 and RSAD2. Cell Signal.
34:55–65. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Han X, Li R, Zhang W, Yang X, Wheeler CG,
Friedman GK, Province P, Ding Q, You Z, Fathallah-Shaykh HM, et al:
Expression of PRMT5 correlates with malignant grade in gliomas and
plays a pivotal role in tumor growth in vitro. J Neurooncol.
118:61–72. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ibrahim R, Matsubara D, Osman W, Morikawa
T, Goto A, Morita S, Ishikawa S, Aburatani H, Takai D, Nakajima J,
et al: Expression of PRMT5 in lung adenocarcinoma and its
significance in epithelial-mesenchymal transition. Hum Pathol.
45:1397–1405. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tanaka H, Hoshikawa Y, Oh-hara T, Koike S,
Naito M, Noda T, Arai H, Tsuruo T and Fujita N: PRMT5, a novel
TRAIL receptor-binding protein, inhibits TRAIL-induced apoptosis
via nuclear factor-kappaB activation. Mol Cancer Res. 7:557–569.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang B, Dong S, Li Z, Lu L, Zhang S, Chen
X, Cen X and Wu Y: Targeting protein arginine methyltransferase 5
inhibits human hepatocellular carcinoma growth via the
downregulation of beta-catenin. J Transl Med. 13:3492015.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang B, Dong S, Zhu R, Hu C, Hou J, Li Y,
Zhao Q, Shao X, Bu Q, Li H, et al: Targeting protein arginine
methyltransferase 5 inhibits colorectal cancer growth by decreasing
arginine methylation of eIF4E and FGFR3. Oncotarget. 6:22799–22811.
2015.PubMed/NCBI
|
|
16
|
Deng X, Von Keudell G, Suzuki T, Dohmae N,
Nakakido M, Piao L, Yoshioka Y, Nakamura Y and Hamamoto R: PRMT1
promotes mitosis of cancer cells through arginine methylation of
INCENP. Oncotarget. 6:35173–35182. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Greenblatt SM, Liu F and Nimer SD:
Arginine methyltransferases in normal and malignant hematopoiesis.
Exp Hematol. 44:435–441. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sonohara F, Inokawa Y, Hayashi M, Kodera Y
and Nomoto S: Epigenetic modulation associated with carcinogenesis
and prognosis of human gastric cancer. Oncol Lett. 13:3363–3368.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cheng D, Yadav N, King RW, Swanson MS,
Weinstein EJ and Bedford MT: Small molecule regulators of protein
arginine methyltransferases. J Biol Chem. 279:23892–23899. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Castellano S, Milite C, Ragno R, Simeoni
S, Mai A, Limongelli V, Novellino E, Bauer I, Brosch G, Spannhoff
A, et al: Design, synthesis and biological evaluation of carboxy
analogues of arginine methyltransferase inhibitor 1 (AMI-1). Chem
Med Chem. 5:398–414. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Peng X, Yu H, Hang Y and Wang J:
N,N'-phosgenation with triphosgene in the synthesis of direct dyes
containing the ureylene group. Dyes Pigments. 32:193–198. 1996.
View Article : Google Scholar
|
|
22
|
Ragno R, Simeoni S, Castellano S,
Vicidomini C, Mai A, Caroli A, Tramontano A, Bonaccini C, Trojer P,
Bauer I, et al: Small molecule inhibitors of histone arginine
methyltransferases: Homology modeling, molecular docking, binding
mode analysis, and biological evaluations. J Med Chem.
50:1241–1253. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Andreu-Perez P, Hernandez-Losa J, Moline
T, Gil R, Grueso J, Pujol A, Cortés J, Avila MA and Recio JA:
Methylthioadenosine (MTA) inhibits melanoma cell proliferation and
in vivo tumor growth. BMC Cancer. 10:2652010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ansorena E, Garcia-Trevijano ER,
Martinez-Chantar ML, Huang ZZ, Chen L, Mato JM, Iraburu M, Lu SC
and Avila MA: S-adenosylmethionine and methylthioadenosine are
antiapoptotic in cultured rat hepatocytes but proapoptotic in human
hepatoma cells. Hepatology. 35:274–280. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li TW, Zhang Q, Oh P, Xia M, Chen H,
Bemanian S, Lastra N, Circ M, Moyer MP, Mato JM, et al:
S-Adenosylmethionine and methylthioadenosine inhibit cellular FLICE
inhibitory protein expression and induce apoptosis in colon cancer
cells. Mol Pharmacol. 76:192–200. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang B, Zhang S, Zhu L, Chen X, Zhao Y,
Chao L, Zhou J, Wang X, Zhang X and Ma N: Arginine
methyltransferase inhibitor 1 inhibits gastric cancer by
downregulating eIF4E and targeting PRMT5. Toxicol Appl Pharmacol.
336:1–7. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Poulard C, Corbo L and Le Romancer M:
Protein arginine methylation/demethylation and cancer. Oncotarget.
7:67532–67550. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bedford MT and Clarke SG: Protein arginine
methylation in mammals: Who, what, and why. Mol Cell. 33:1–13.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Andrade AF, Borges KS, Castro-Gamero AM,
Silveira VS, Suazo VK, Oliveira JC, Moreno DA, de Paula Queiroz RG,
Scrideli CA and Tone LG: Zebularine induces chemosensitization to
methotrexate and efficiently decreases AhR gene methylation in
childhood acute lymphoblastic leukemia cells. Anticancer Drugs.
25:72–81. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Herr I and Debatin KM: Cellular stress
response and apoptosis in cancer therapy. Blood. 98:2603–2614.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zurita-Lopez CI, Sandberg T, Kelly R and
Clarke SG: Human protein arginine methyltransferase 7 (PRMT7) is a
type III enzyme forming omega-NG-monomethylated arginine residues.
J Biol Chem. 287:7859–7870. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Feng Y, Maity R, Whitelegge JP,
Hadjikyriacou A, Li Z, Zurita-Lopez C, Al-Hadid Q, Clark AT,
Bedford MT, Masson JY and Clarke SG: Mammalian protein arginine
methyltransferase 7 (PRMT7) specifically targets RXR sites in
lysine- and arginine-rich regions. J Biol Chem. 288:37010–37025.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cha B and Jho EH: Protein arginine
methyltransferases (PRMTs) as therapeutic targets. Expert Opin Ther
Targets. 16:651–664. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bhaumik SR, Smith E and Shilatifard A:
Covalent modifications of histones during development and disease
pathogenesis. Nat Struct Mol Biol. 14:1008–1016. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Balint BL, Szanto A, Madi A, Bauer UM,
Gabor P, Benko S, Puskás LG, Davies PJ and Nagy L: Arginine
methylation provides epigenetic transcription memory for
retinoid-induced differentiation in myeloid cells. Mol Cell Biol.
25:5648–5663. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Litt M, Qiu Y and Huang S: Histone
arginine methylations: Their roles in chromatin dynamics and
transcriptional regulation. Biosci Rep. 29:131–141. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bedford MT and Richard S: Arginine
methylation an emerging regulator of protein function. Mol Cell.
18:263–272. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ma WL, Wang L, Liu LX and Wang XL: Effect
of phosphorylation and methylation on the function of the p16INK4a
protein in non-small cell lung cancer A549 cells. Oncol Lett.
10:2277–2282. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Jansson M, Durant ST, Cho EC, Sheahan S,
Edelmann M, Kessler B and La Thangue NB: Arginine methylation
regulates the p53 response. Nat Cell Biol. 10:1431–1439. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Li Y, Chitnis N, Nakagawa H, Kita Y,
Natsugoe S, Yang Y, Li Z, Wasik M, Klein-Szanto AJ, Rustgi AK and
Diehl JA: PRMT5 is required for lymphomagenesis triggered by
multiple oncogenic drivers. Cancer Discov. 5:288–303. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Muller PA and Vousden KH: Mutant p53 in
cancer: New functions and therapeutic opportunities. Cancer Cell.
25:304–317. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Li Y and Diehl JA: PRMT5-dependent p53
escape in tumorigenesis. Oncoscience. 2:700–702. 2015. View Article : Google Scholar : PubMed/NCBI
|
